RF Beauty Devices to Require Class III Medical Device Registration from April 2026

Starting April 1, 2026, China's National Medical Products Administration (NMPA) will classify radiofrequency (RF) beauty devices, including RF treatment and skin therapy equipment, as Class III medical devices. This regulatory change mandates that all such products must obtain NMPA registration certificates before production, import, or sale in China. The policy significantly impacts overseas suppliers, importers, and distributors, requiring immediate compliance checks to avoid customs clearance issues.

Event Overview

From April 1, 2026, RF beauty devices will fall under China's strictest medical device category (Class III). Unregistered products will be prohibited from manufacturing, importing, or selling in China. The NMPA's decision reflects heightened scrutiny over non-invasive aesthetic devices, aligning them with higher-risk medical equipment standards.

Industries Affected

1. Overseas Manufacturers & Exporters

Companies producing RF beauty devices for the Chinese market must now complete lengthy NMPA registration (typically 12-24 months). Failure to obtain certification will block market access.

2. Importers & Distributors

Customs will reject shipments lacking proper documentation. Distributors must verify suppliers' NMPA certificates before placing orders to prevent supply chain disruptions.

3. E-commerce Cross-border Sellers

Platforms may delist non-compliant RF devices. Sellers should audit inventory and halt pre-orders for unregistered products.

Key Actions for Businesses

1. Verify Supplier Compliance Immediately

Request NMPA registration certificates from Chinese partners. Cross-check with official databases to avoid fraudulent documents.

2. Adjust Procurement Timelines

Factor in extended lead times (12+ months) for new product registrations. Prioritize existing certified suppliers.

3. Prepare Contingency Plans

Identify alternative Class III-certified products or explore non-RF beauty technologies to maintain product portfolios.

Industry Perspective

This policy signals China's tightening control over aesthetic devices. While improving safety standards, it creates substantial barriers for foreign brands. The industry should expect:

• Increased consolidation among certified manufacturers
• Higher compliance costs potentially raising retail prices
• Stricter platform enforcement during 2025-2026 transition

Conclusion

The NMPA's reclassification represents a pivotal shift in China's beauty device regulations. Businesses must treat this as an urgent compliance priority rather than a distant deadline, given the lengthy registration process. Early adaptation will be crucial for maintaining market access.

Source Information

National Medical Products Administration (NMPA) official announcement, March 2024. Ongoing monitoring required for implementation details and potential grace period clarifications.